Arcus Bioscience Stock Price, News & Analysis

Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.

Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.

Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.

Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.

On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.

Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.